Skip to main content

Table 1 Tumour incidence rate after human mesenchymal stem cell (MSCs) transplantation in healthy, acute liver failure (ALF), and alcoholic liver disease (ALD) non-obese diabetic severe combined immune-deficient (NOD/SCID) mice

From: Co-stimulation of LPAR1 and S1PR1/3 increases the transplantation efficacy of human mesenchymal stem cells in drug-induced and alcoholic liver diseases

Model Test item Injected cell number No. of tumour-bearing micea Tumour incidence rate (%)
Healthy mice MRC-5b 1 × 107 0/12 0
hADMSCs 1 × 107 0/12 0
hADMSCs with LPA/S1Pc 1 × 107 0/12 0
ES-D3d 1 × 107 10/10 100
ALF model MRC-5 1 × 107 0/9 0
hADMSCs 1 × 107 0/12 0
hADMSCs with LPA/S1P 1 × 107 0/15 0
ES-D3 1 × 107 9/9 100
ALD model MRC-5 1 × 107 0/12 0
hADMSCs 1 × 107 0/12 0
hADMSCs with LPA/S1P 1 × 107 0/12 0
ES-D3 1 × 107 11/11 100
  1. hADMSC, human adipose-derived mesenchymal stem cell; LPA, lysophosphatidic acid; S1P, sphingosine-1-phosphate
  2. aDead mice during experiments were not calculated
  3. bNegative control group
  4. cPre-treated with 5 μM LPA and 0.25 μM S1P for 2 h before stem cell transplantation
  5. dPositive control group